Science
Antibody-Based Therapeutics
Driven by our deep and longstanding experience developing antibody-based immunotherapies, Celldex’s proprietary antibody programs and technologies are supported by robust in-house capabilities, enabling the optimized discovery and development of innovative scientific programs.
Deep and longstanding experience developing antibody-based immunotherapies
Celldex was founded based on a fundamental scientific belief that harnessing the power of immunology would break significant barriers in drug development for a variety of devastating diseases. Our scientific philosophy is derived from longstanding roots in the antibody and immunotherapy field and we continue to strive to deliver breakthrough technologies.
Cutting edge science with patient-focused approach
Our development programs are designed to deliver life-changing therapies for patients with significant medical needs with limited or no treatment options. As we look to the future, we believe the next great challenge for the field is the development of therapies that seek to go beyond managing symptoms to returning the immune system to its purpose and improving the lives of patients with allergic, inflammatory and autoimmune disorders.
Proprietary antibody programs using validated technologies drive innovation
Celldex draws upon a number of core technologies to design targeted therapeutic candidates that seek to leverage the power of the immune system to fight disease. Our programs encompass validated technologies including optimized monoclonal and bispecific antibodies that can be exploited for specific therapeutic applications. Our comprehensive approach provides us with a unique capacity to tackle human diseases based on the newest scientific understanding and technologies.
Next Generation Bispecific Antibody Platform
Our next generation bispecific antibody platform is supporting the expansion of additional candidates for inflammatory diseases. Bispecific antibodies can engage two independent pathways involved in promoting inflammation and combining these into one molecule may drive greater therapeutic activity.
Targets are being selected based on emerging science and their compatibility to be used in bispecific antibody formats with combinations of Celldex’s existing antibody programs. Lead bispecific antibodies in development are targeting key pathways involved in driving inflammatory and fibrotic diseases.
Robust in-house capabilities enable optimized development process
Celldex’s strong in-house capabilities enable us to effectively and efficiently advance our development programs from antibody discovery and engineering to GMP manufacturing. Keeping these activities in-house provides us with a high level of control over multiple processes and ensures a unique element of focus and expertise for our scientific programs. Our team has deep experience with managing complex infrastructure, proficiency in several different technologies and extensive analytical capabilities.
Publications
Treatment with Barzolvolimab Leads to Sustained Improvement in Angioedema in Patients with Chronic Spontaneous Urticaria (CSU): Results from 52 Weeks of Treatment
Learn MoreSustained Disease Control Following Withdrawal of Barzolvolimab in Patients with Chronic Spontaneous Urticaria
Learn MoreDellon, et al, DDW 2025, May 2025
Intraepithelial Mast Cells are Elevated in Active Eosinophilic Esophagitis and Correlate with Eosinophils: Baseline Data from a Randomized Controlled Trial of Barzolvolimab
Learn MoreTreatment with Barzolvolimab Improves Urticaria Control and Quality of Life in Patients with Chronic Inducible Urticaria: Phase 2 12 Week Results
Learn MoreBarzolvolimab Improves Urticaria Control and Quality of Life in Patients with Chronic Spontaneous Urticaria: 52-Week Data
Learn MoreAlvarado et al, AAAAI, March 2025
Dual Targeting of Mast Cells and TSLP with the Bispecific Antibody CDX-622
Learn MoreMurphy, et al, Allergy, February 2025
Dual Inhibition of Mast Cells and Thymic Stromal Lymphopoietin Using a Novel Bispecific Antibody, CDX-622
Learn MoreMaurer et al, ACAAI, October 2024
Positive Efficacy and Favorable Safety of Barzolvolimab in Chronic Inducible Urticaria: Phase 2 Trial Results
Learn MoreMetz et al, EADV, September 2024
Barzolvolimab shows profound efficacy and favorable safety over 52 weeks in patients with Chronic Spontaneous Urticaria
Learn MoreMaurer et al, EAACI, June 2024
Barzolvolimab Significantly Improves Angioedema in Patients with Chronic Spontaneous Urticaria (CSU): Results from a Phase 2 Trial
Learn MoreMaurer et al, AAAAI, February 2024
Barzolvolimab Significantly Decreases Chronic Spontaneous Urticaria Disease Activity and is Well Tolerated: Top Line Results from a Phase 2 Trial
Learn MoreMetz et al, WCI, November 2023
Barzolvolimab Demonstrates Safety and Clinically Meaningful Activity in Moderate-Severe Prurigo Nodularis
Learn MoreMaurer et al, EADV, October 2023
Patients With Chronic Spontaneous Urticaria Experience Improvement in Quality of Life When Treated With Barzolvolimab
Learn MoreMaurer et al, EAACI, June 2023
Barzolvolimab Demonstrates Clinical Activity in a Multiple Ascending Dose Trial in Chronic Spontaneous Urticaria
Learn MoreDual Targeting of Mast Cells and TSLP with a Bispecific Antibody
Learn MoreMaurer et al, AAAAI, February 2023
Safety and Clinical Activity of Multiple Doses of Barzolvolimab, an anti-KIT Antibody, in Patients with Chronic Spontaneous Urticaria
Learn MoreMaurer et al, GUF, December 2022
Barzolvolimab-induced response and mast cell suppression are durable and linked
Learn MoreMaurer et al, GUF, December 2022
Cold urticaria patients achieve complete response with 1.5 mg/kg barzolvolimab
Learn MoreEncore: Maurer et al, GUF, December 2022
Multi-dosed barzolvolimab is effective in chronic spontaneous urticaria
Learn MoreEncore: Maurer et al, GUF, December 2022
Mast cell reduction does not impair human cutaneous wound healing
Learn MoreMaurer et al, EAACI, July 2022
Effects of Multiple Dose Treatment with an Anti-KIT Antibody, CDX-0159, in Chronic Spontaneous Urticaria
Learn MoreAlvarado et al, Allergy, February 2022
Anti-KIT monoclonal antibody CDX-0159 induces profound and durable mast cell suppression in a healthy volunteer study
Learn MoreEncore: Maurer et al, AAAAI, February 2022
The Anti-KIT Antibody, CDX-0159, Reduces Mast Cell Numbers and Circulating Tryptase and Improves Disease Control in Patients with Chronic Inducible Urticaria
Learn MoreMaurer et al, EADV, September 2021
CDX-0159, an anti-KIT Antibody, Demonstrates Rapid and Sustained Clinical Response and Improved Quality of Life in Patients with Chronic Inducible Urticaria
Learn MoreMaurer et al, EAACI, July 2021
The Anti-kit Antibody, CDX-0159, Reduces Disease Activity and Tryptase Levels in Patients with Chronic Inducible Urticaria
Learn MoreVitale et al, AACR 2021 Poster, April 2021
Simultaneous De-repression of Innate and Adaptive Immune Responses Through Dual Targeting of ILT4 and PD-(L)1 with Bispecific Antibodies
Learn MoreMaurer et al, EAACI, June 2020
CDX-0159, an anti-KIT monoclonal antibody, demonstrates dose-dependent reductions in plasma Tryptase and a favorable safety profile in a Phase 1a healthy volunteer study
Learn MoreSeibel et al, ACAAI, November 2019
CDX-0159, an anti-KIT monoclonal antibody, as a modulator of mast cell-related diseases
Learn More